Jane Street
AKRO

Jane Street’s Akero Therapeutics AKRO Stock Holding History

Jane Street’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,500
Closed -$831K – 11001
2025
Q3 		$831K Sell
17,500
-108,400
-86% -$5.25M ﹤0.01% 6721
2025
Q2 		$6.72M Buy
125,900
+77,500
+160% +$3.52M ﹤0.01% 2624
2025
Q1 		$1.96M Buy
48,400
+39,300
+432% +$1.67M ﹤0.01% 4383
2024
Q4 		$253K Sell
9,100
-1,000
-10% -$30.3K ﹤0.01% 8017
2024
Q3 		$290K Sell
10,100
-4,800
-32% -$125K ﹤0.01% 8093
2024
Q2 		$350K Sell
14,900
-12,300
-45% -$263K ﹤0.01% 7555
2024
Q1 		$687K Sell
27,200
-54,600
-67% -$1.31M ﹤0.01% 6115
2023
Q4 		$1.91M Sell
81,800
-135,800
-62% -$2.68M ﹤0.01% 4403
2023
Q3 		$11M Buy
217,600
+189,000
+661% +$8.8M ﹤0.01% 1680
2023
Q2 		$1.34M Sell
28,600
-94,100
-77% -$4.31M ﹤0.01% 4766
2023
Q1 		$4.69M Sell
122,700
-4,600
-4% -$205K ﹤0.01% 2550
2022
Q4 		$6.98M Buy
127,300
+17,900
+16% +$767K ﹤0.01% 2049
2022
Q3 		$3.73M Buy
+109,400
New +$1.67M ﹤0.01% 3096

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jane Street's AKRO Position: Q4 2025 in Review

Jane Street sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,949 shares — an estimated $377K sold.

Jane Street first reported a position in AKRO in Q1 2021 and held it in 18 quarters. The position peaked at $12.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Jane Street reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 7,949 Akero Therapeutics shares in Q4 2025, an estimated $377K.
  • Jane Street first reported a position in Akero Therapeutics in Q1 2021 and held it in 18 quarters.
  • Jane Street's Akero Therapeutics position peaked at $12.3M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.